Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interferon Alpha Therapy for Cervical CIN I and HPV Infection
NCT06137950Phase 1Completed
- Sponsor
- Mongolian National University of Medical Sciences
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of antiviral lozenge in human papillomavirus infection and cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by Mongolian National University of Medical Sciences. Primary endpoints: Pap smear at 90 days and Colposcopic change at 90 days. Started Nov 2023; status: completed.
02
Drugs
antiviral lozenge
03
Conditions
human papillomavirus infectioncervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT06137950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137950.